At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
UNCY Unicycive Therapeutics, Inc.
Trading 02-24 14:18:16 EST
6.86
+0.29
+4.41%
High6.99Low6.50Vol678.32K
Open6.56D1 Closing6.57Amplitude7.46%
Mkt Cap147.43MTradable Cap89.23MTotal Shares21.49M
T/O4.66MT/O Rate5.21%Tradable Shares13.01M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Unicycive Therapeutics management to meet with Piper Sandler
TIPRANKS  ·  02-20
Unicycive Therapeutics management to meet with Piper Sandler
Unicycive Therapeutics initiated with a Buy at WestPark Capital
TIPRANKS  ·  02-19
Unicycive Therapeutics initiated with a Buy at WestPark Capital
Unicycive Therapeutics Faces Shareholder Lawsuit Over Alleged False Statements
Reuters  ·  02-17
Unicycive Therapeutics Faces Shareholder Lawsuit Over Alleged False Statements
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and Launch Plans for OLC
Reuters  ·  02-07
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and Launch Plans for OLC
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
GlobeNewswire  ·  02-04
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
Unicycive Therapeutics Showcases Pipeline Advancements in Kidney Disease Treatments
Reuters  ·  01-31
Unicycive Therapeutics Showcases Pipeline Advancements in Kidney Disease Treatments
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY)
TIPRANKS  ·  01-30
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY)
De-Risked Regulatory Path and Commercial Readiness Underpin Buy Rating on Unicycive and Lead Asset OLC
TIPRANKS  ·  01-30
De-Risked Regulatory Path and Commercial Readiness Underpin Buy Rating on Unicycive and Lead Asset OLC
BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin
Reuters  ·  01-29
BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin
Unicycive Therapeutics Inc - FDA Assigns Pdufa Target Date of June 29, 2026
THOMSON REUTERS  ·  01-29
Unicycive Therapeutics Inc - FDA Assigns Pdufa Target Date of June 29, 2026
Update - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (Olc) New Drug Application (Nda) Resubmission
THOMSON REUTERS  ·  01-29
Update - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (Olc) New Drug Application (Nda) Resubmission
BUZZ-Unicycive rises as FDA accepts resubmitted filing for kidney drug
Reuters  ·  01-29
BUZZ-Unicycive rises as FDA accepts resubmitted filing for kidney drug
Unicycive Therapeutics Inc - Pdufa Target Action Date Set for June 27, 2026
THOMSON REUTERS  ·  01-29
Unicycive Therapeutics Inc - Pdufa Target Action Date Set for June 27, 2026
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
GlobeNewswire  ·  01-29
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Launch Plans in New Presentation
Reuters  ·  01-08
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Launch Plans in New Presentation
Unicycive Resubmits NDA for Oxylanthanum Carbonate to FDA
Reuters  ·  2025-12-29
Unicycive Resubmits NDA for Oxylanthanum Carbonate to FDA
Unicycive Therapeutics Inc - Nda Submission Review Expected Within 6 Months per Prescription Drug User Fee Act
THOMSON REUTERS  ·  2025-12-29
Unicycive Therapeutics Inc - Nda Submission Review Expected Within 6 Months per Prescription Drug User Fee Act
Unicycive Therapeutics Inc - Nda Resubmitted After Vendor Resolves FDA Deficiencies
THOMSON REUTERS  ·  2025-12-29
Unicycive Therapeutics Inc - Nda Resubmitted After Vendor Resolves FDA Deficiencies
Unicycive Therapeutics Announces Resubmission of New Drug Application (Nda) for Oxylanthanum Carbonate (Olc)
THOMSON REUTERS  ·  2025-12-29
Unicycive Therapeutics Announces Resubmission of New Drug Application (Nda) for Oxylanthanum Carbonate (Olc)
Unicycive Therapeutics unveils new kidney disease treatment pipeline in latest corporate presentation
Reuters  ·  2025-12-03
Unicycive Therapeutics unveils new kidney disease treatment pipeline in latest corporate presentation

Introduction

Company Name.
Unicycive Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Issue price:
--